HER2/Mesothelin/CD30 targeted IL-12 Development Service
Creative Biolabs directly addresses the fundamental safety challenge associated with interleukin-12 (IL-12)—the severe, dose-limiting toxicities caused by uncontrolled systemic cytokine release, as documented in clinical trials. We provide specialized, end-to-end development pathways that ensure IL-12's potent T-helper 1 (Th1) polarizing activity is confined exclusively to the tumor site. This strategic focus enhances the therapeutic index and promotes durable anti-tumor responses against both primary tumors and metastatic disease.
Background What We Can Offer Workflow Why Choose Us FAQs Customer Review Related Services Contact Us
Strategic Target Selection: HER2, Mesothelin, and CD30
Our development services focus on three strategically selected, high-value tumor-associated antigens (TAAs) known for high expression across devastating cancer types, offering broad therapeutic applicability:
|
Target
|
Mechanism of Action (IL-12 Specific)
|
Key Indications
|
|
HER2 (ERBB2)
|
High cell-surface expression in various solid tumors. Enables precise delivery to Herceptin-refractory or low-HER2 expressing tumors, potentially synergizing with existing standard of care.
|
Breast, Gastric, Esophageal, Colorectal Cancers
|
|
Mesothelin (MSLN)
|
Near-ubiquitous expression in certain deadly cancers, with limited expression in normal tissues (excluding mesothelial cells). Ideal for targeting difficult-to-treat malignancies.
|
Adenocarcinoma, Ovarian Cancer
|
|
CD30
|
A member of the TNF receptor superfamily, primarily restricted to hematological malignancies (hodgkin lymphoma, anaplastic large cell lymphoma) and embryonal carcinomas. Enables treatment of tumors with well-defined surface markers.
|
Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Testicular Germ Cell Tumors
|
Core Targeted IL-12 Delivery Platforms
High-Affinity Immunocytokine (ICC) Production
Fusing functional IL-12 to a targeting moiety (e.g., mAb, scFv) specific for high-value tumor-associated antigens (TAAs) like HER2, mesothelin, or CD30. This acts as a "dose shield" to maximize tumor accumulation.
Cellular Engine Engineering (mbIL-12)
Engineering CAR T or TCR T cells to express membrane-bound IL-12 (mbIL-12). This provides a localized, autocrine/paracrine cytokine booster upon antigen engagement in the tumor microenvironment (TME), improving T cell persistence in solid tumors.
Safety Switch Integration (Masked Cytokines)
Developing initially inactive, "masked IL-12 variants" that are specifically activated by tumor-associated proteases (like MMPs) within the TME, enhancing safety and specificity.
Discover How We Can Help - Request a Consultation to discuss which precision platform is right for your oncology target.
Workflow: From Concept to Clinically Relevant Construct
Our project workflow is designed for clarity and rigorous quality control, providing potential clients with a detailed roadmap of the development process.
Why Choose Us?
Key Advantages in Precision Targeting
Precision Targeting and Strategic TAA Selection
We focus on strategic target selection, including HER2, mesothelin, and CD30, which exhibit high expression in target tumors but limited expression on vital normal tissue. This minimizes off-target toxicity, addressing the primary concern raised by historical clinical trials of non-targeted IL-12.
Safety Profile Enhancement through Dose Shielding
Our immunocytokines are designed to reduce systemic bioavailability and toxicity compared to non-targeted IL-12. This demonstrated dose-shielding effect significantly widens the therapeutic window, allowing for higher, more effective doses to be localized at the disease site.
Dual-Function mbIL-12 Platforms
Our cell-mediated approach provides both targeting (via CAR/TCR) and autocrine/paracrine T-cell boosting in situ. This addresses the immune desert challenge in solid tumors, leading to enhanced T cell persistence and superior recursive killing, echoing the critical T-cell dependent mechanisms noted in successful preclinical tumor rejection models.
Validated Functional Integrity
We apply rigorous characterization using advanced biophysical techniques. This ensures the IL-12 functional integrity is not compromised by the fusion or engineering process, providing quantitative evidence that the engineered product behaves as expected.
Experience the Creative Biolabs Advantage - Get a Quote Today and accelerate your path to a safer, more effective immunotherapy solution.
FAQs
Q: What is the primary advantage of your ICC over systemic recombinant IL-12?
A: Our ICCs offer a significantly wider therapeutic index. The antibody component acts as a "dose shield" in circulation, drastically reducing systemic exposure and the associated toxicities, while actively accumulating the IL-12 payload at the tumor site.
Q: Can I use this service if my target antigen is not HER2, Mesothelin, or CD30?
A: Absolutely. While we strategically focus on these high-value TAAs, our platform is fully customizable. We can rapidly develop and optimize targeting moieties for virtually any cell-surface antigen relevant to your specific oncology project.
Q: Are there any limitations or necessary precautions I should be aware of when developing an IL-12 immunocytokine?
A: The main precaution is selecting a TAA with low or restricted expression on vital normal tissues to minimize off-target effects. We help mitigate this risk during the target selection and optimization phase by focusing on TAAs like mesothelin, which has limited normal tissue expression outside of certain cells.
Customer Review
-
Enhanced Therapeutic Index
Using Creative Biolabs' service in our research has significantly facilitated the preclinical safety profile of our pancreatic adenocarcinoma therapy. The mesothelin-targeted ICC demonstrated excellent dose shielding, moving us closer to a clinically viable product. - Sarah P***on
-
Functional Integrity Validation
Their SPR/BLI binding affinity analysis confirmed that the masking domain was cleavable by tumor proteases without compromising the native IL-12R binding post-cleavage. - A. M. H***ley
Related Services
To further enhance your immunotherapy pipeline, Creative Biolabs recommends exploring these complementary services:
Next Immunocytokine Engineering Development Service
Creative Biolabs offers customized immunocytokine engineering by fusing cytokines with targeting proteins (e.g., antibodies) to modulate localization, minimize systemic toxicity, and enhance TME therapeutic efficacy.
Learn More →
Anti-inflammatory Cytokine Panel Screening Service
Creative Biolabs offers an anti-inflammatory cytokine panel screening service (ELISA, multiplex bead-based assays) to analyze IL-10, TGF-β, IL-4, and more, assessing inflammatory profiles for chronic conditions and treatment monitoring.
Learn More →
How to Contact Creative Biolabs
Creative Biolabs' HER2/mesothelin/CD30 targeted IL-12 development service provides the critical technology needed to transform IL-12 from a systemically toxic molecule into a precise, potent, and safe tumor-localized therapeutic agent. By leveraging immunocytokines, mbIL-12, and protease-activated variants, we are committed to accelerating the development of next-generation cancer therapeutics.
To take the first step in developing your targeted cytokine therapy, please reach out to our expert team for a detailed discussion about your project and to receive a customized proposal.
